Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Randomized Study of SU011248 versus Interferon-alpha in Metastatic Renal Cell Carcinoma
2004-001149-14Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sunitinib in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Pfizer. Started Mar 2005; status: completed.
02
Drugs
sunitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2004-001149-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001149-14.